BioStem Technologies, a leading MedTech company focused on the development, manufacturing, and commercialisation of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief Financial Officer (CFO). Poe has served on BioStem’s Board of Directors since 2022. Michael Fortunato, the Company’s prior CFO, has assumed the role of Chief Accounting Officer.

“I’m excited to welcome Brandon as CFO during this pivotal period of growth and innovation for BioStem,” said Jason Matuszewski, Chairman and CEO. “Brandon brings proven financial leadership across life sciences, medical devices, and healthcare services, with deep expertise in capital markets, strategic planning, and operational excellence. His contributions as a Board member have already proven invaluable, and his intimate knowledge of our business will be a powerful advantage as we expand into new markets, advance our Nasdaq uplisting, and deliver on our long-term growth ambitions.”

Poe is an accomplished finance leader with more than 25 years of experience across the healthcare and life sciences sectors. He most recently served as Chief Financial Officer of Midi Health, Inc., a privately held digital women’s healthcare company. Before that, he was Chief Financial Officer of Jumpcode Genomics, Inc., a privately held life sciences company. Earlier in his career, Poe spent eight years at Illumina, Inc. (NASDAQ: ILMN), a publicly traded life sciences company, where he served in multiple senior finance roles, most recently as Vice President of Finance for Product Development, Research and Global Operations. Poe holds an undergraduate degree from Bucknell University and an MBA from the University of Chicago’s Booth School of Business.